|
|
|
|
World Courier
|
|
Customising the Cold Chain
|
|
Of all the statistics emerging around the global pharmaceutical industry
this year, two big numbers capture the attention of both manufacturers
and their logistics partners: $248 billion, the amount the “BRIC”
nations (Brazil, Russia, India and China) are poised to account for in
pharmaceutical sales for by 2016; and $8 billion, the amount global
pharma will spend on cold chain logistics in 2014. Why are these two
numbers so noteworthy? They demonstrate that as R&D goes, so goes
logistics. As products evolve to meet demands for more targeted
therapies, demand for more targeted logistics solutions grows as well.
And that means a need for customization for everything from clinical
trial samples to finished product.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Aragen launches royalty-free CHO GS cell line development platform under RapTr2022
Delivers Titres up to 6g/L; Transfection to RCB in 18 weeks; RapTr2022 supports CHO GS and DG 44
More info >> |
|
 |
White Papers |
 |
|
Medpace Reference Laboratories establishes state of the art Flow Cytometry techniques for flexible approaches to clinical trials across multiple therapeutic areas.
Medpace
Cytometry is the process of measuring the properties of individual cells. These properties may include gene or protein expression, chemical properties, deoxyribonucleic acid (DNA) content, and various cellular functions. The earliest methods of cytometry relied upon light microscopy for the classification and observation of cells and cellular components. Microscopy permitted direct visual observation of cells for the first time, leading to the classification of cells by morphology and insight into cellular functions. However, the time required for microscopic analysis constrains the number of samples or number of cells in each sample that can be examined. Therefore, the utility of microscopy for analysis of rare cells or in situations where sample throughput is a priority is limited. Flow cytometry was developed largely to improve upon these limitations.
More info >> |
|
|
|
